Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : InterMune (nasdaq)ITMN -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (97)	5/25/2001 3:18:28 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 508

I just got around to listening to the UBS conference. Much of the info presented by Scott Harkonen was already known and I will skip most of it. One statement worth repeating was the statement that Actimunne is protected by a composition of matter patent til 2015. Other points made: - Actimmune's mode of action is both (1) antiproliferative and (2) antimicrobial - the antiproliferative properties, reduce fibrosis, reduce excess bone growth and reduce the growth of cancer cells - the antimicrobial effect comes by concentrating antibiotics in the bacteria thus accelerating aptosis - enrollment in IPF PIII is on track with 180 in out of 260 planned - enrollment at additional sites in EU will continue after the US target of 6/30 until 8/31 - Phase III in ovarian cancer will start soon One statement was made that seemed stronger than I have heard up til now. Here it is as best I could catch the quote: "Actimmune, interestingly and remarkably, I think, the holy grail had been to try to reduce, slow down, the progression of this disease. The studies that I will show you - showed that, in early disease, Actimmune actually reverses fibrosis and restores lung function." As always - Please feel free to listen to the call and correct anything that I may have misunderstood. ij